Skip to main content

Paying for Treatment

Diabetic foot ulcers are a common and costly complication for people with diabetes. ON101 is a promising new topical treatment anticipated for FDA approval in the coming...
CMS initiates drug price negotiations, targeting diabetes drugs among others. Resulting from the Inflation Reduction Act, it aims for cost cuts by 2026, benefiting...
Amazon Pharmacy now auto-applies coupons to insulins and other diabetes supplies. See how you can save money and time.
Brenzavvy, an affordable FDA-approved Type 2 diabetes drug, now accessible via Cost Plus Drugs, aids in effective glucose management and diabetes control.
At the 17th annual Diabetes Forum at ADA 2023, the diaTribe Foundation and TCOYD moderated an expert panel that discussed access and equity issues, breakthrough...
UnitedHealthcare begins coverage for CGM in people with type 2 diabetes.
On April 16, Medicare began covering people with type 2 diabetes for continuous glucose monitors (CGMs).
Following Eli Lilly’s recent announcement of a $35 monthly limit on out-of pocket costs, Sanofi announced a $35 cost cap on Lantus, and Novo Nordisk pledged to reduce...
Eli Lilly announced today that it will cut the list prices for its most commonly prescribed insulins, including Humalog and Humulin, by 70%. The drug maker will also...
Health insurance options can be overwhelming, especially when you have a condition like diabetes. Here’s how to compare options and make sure you have the coverage you...
The recently passed Inflation Reduction Act includes new policies that cap the monthly cost of insulin at $35 and potentially reduce the cost of other diabetes drugs for...
Under a new federal rule from the Centers for Medicare and Medicaid Services (CMS), those insured by employer health plans will now have access to significantly more...
The financial burden of managing diabetes can be overwhelming. Sanofi has updated its Valyou Savings Program to make insulin more affordable for those who are uninsured...
Civica, a nonprofit pharmaceutical company, announced plans to make generic insulin available for $30 per vial or $55 for five prefilled pens, regardless of insurance...
US pharmaceutical companies and insulin manufacturers react to proposed legislation that would cap insulin costs and prevent significant rises in the costs of...
Lilly’s new basal insulin, Rezvoglar, may provide a cheaper alternative to Lantus. This marks the second approval of a biosimilar long-acting insulin.
As we approach the new year, we want to remind you that if you've met your annual health insurance deductible or are close to meeting it, do not forget to order any...
A compromise reached among Congress and the Biden-Harris Administration would add a drug pricing plan to the Build Back Better Act that includes an insulin copay cap, a...
Have you or someone you know had trouble affording diabetes care during COVID-19? During the pandemic, healthcare companies have created programs to help people get...
Ascensia Diabetes Care just launched a new Patient Assistance Program, which is now available in the US. The program aims to reduce out-of-pocket expenses for those who...

Pages